142 related articles for article (PubMed ID: 37676725)
1. Letermovir for pre-emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation.
Kaur R; Purtill D; Cooney J; Cannell P; Wright M; Copeland TS; McGuire M; Boan P
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14147. PubMed ID: 37676725
[TBL] [Abstract][Full Text] [Related]
2. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S
Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768
[TBL] [Abstract][Full Text] [Related]
3. Real world experience with conversion from valganciclovir to letermovir for cytomegalovirus prophylaxis: Letermovir reverses leukopenia and avoids mycophenolate dose reduction.
Jorgenson MR; Descourouez JL; Saddler CM; Smith JA; Odorico JS; Rice JP; Mandelbrot DA
Clin Transplant; 2023 Dec; 37(12):e15142. PubMed ID: 37755141
[TBL] [Abstract][Full Text] [Related]
4. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial.
Liu KY; Wang Y; Han MZ; Huang H; Chen H; Liu QF; Wang JM; Liu T; Song YP; Ma J; Wu DP; Zou P; Huang XJ
Chin Med J (Engl); 2010 Aug; 123(16):2199-205. PubMed ID: 20819665
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
6. Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation.
Chen TT; David AP; Barthelmess EK; MacBrayne CE
Pediatr Blood Cancer; 2023 Nov; 70(11):e30608. PubMed ID: 37548491
[TBL] [Abstract][Full Text] [Related]
7. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection.
Saleh AJ; Al Mohareb F; Al Rabiah F; Chaudhri N; Al Sharif F; Al Zahrani H; Mohamed SY; Patel M; Rasheed W; Nurgat Z; Bakr M; Ahmed S; Zaidi S; Nasser A; Ibrahim K; Al Abdely H; Aljurf M
Hematol Oncol Stem Cell Ther; 2010; 3(3):116-20. PubMed ID: 20890068
[TBL] [Abstract][Full Text] [Related]
8. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
[TBL] [Abstract][Full Text] [Related]
9. Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients.
Körholz KF; Füller MA; Hennies M; Holterhus M; Hagedorn S; Ahlmann M; Thorer H; Burkhardt B; Groll AH
Paediatr Drugs; 2023 Mar; 25(2):225-232. PubMed ID: 36572834
[TBL] [Abstract][Full Text] [Related]
10. Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience.
Febres-Aldana A; Khawaja F; Morado-Aramburo O; Shigle TL; Rondon G; Sassine J; Spallone A; Srinivasan K; Ramdial J; Alousi A; Champlin R; Chen G; Daher M; Rezvani K; Ariza-Heredia EJ; Shpall EJ; Chemaly RF
Clin Microbiol Infect; 2024 Jun; 30(6):803-809. PubMed ID: 38460821
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance.
Lindsay J; Othman J; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Pergam SA; Liu C; Slavin MA; Greenwood M
Transpl Infect Dis; 2021 Jun; 23(3):e13548. PubMed ID: 33342000
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
[TBL] [Abstract][Full Text] [Related]
13. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation.
Ayala E; Greene J; Sandin R; Perkins J; Field T; Tate C; Fields KK; Goldstein S
Bone Marrow Transplant; 2006 May; 37(9):851-6. PubMed ID: 16532016
[TBL] [Abstract][Full Text] [Related]
14. CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre-emptive monitoring in the era of letermovir.
Yong MK; Slavin MA; Chemaly RF; Papanicolaou GA
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14171. PubMed ID: 37864299
[TBL] [Abstract][Full Text] [Related]
15. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters.
Chan ST; Logan AC
Blood Rev; 2017 May; 31(3):173-183. PubMed ID: 28173959
[TBL] [Abstract][Full Text] [Related]
16. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Jung S; Michel M; Stamminger T; Michel D
BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
[TBL] [Abstract][Full Text] [Related]
17. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data.
Pang I; Chen P; Trinh GV; Remberger M; Novitzky-Basso I; Gerbitz A; Kim DD; Kumar R; Lam W; Law AD; Lipton JH; Viswabandya A; Pasic I; Mattsson J; Michelis FV
Eur J Haematol; 2024 Feb; 112(2):301-309. PubMed ID: 37830403
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients.
Saullo JL; Miller RA
Annu Rev Med; 2023 Jan; 74():89-105. PubMed ID: 36332639
[TBL] [Abstract][Full Text] [Related]
19. Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
Takenaka K; Eto T; Nagafuji K; Kamezaki K; Matsuo Y; Yoshimoto G; Harada N; Yoshida M; Henzan H; Takase K; Miyamoto T; Akashi K; Harada M; Teshima T;
Int J Hematol; 2009 Mar; 89(2):231-237. PubMed ID: 19148587
[TBL] [Abstract][Full Text] [Related]
20. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
